|
|
| | 2,3,4,5-Tetrahydro-7-methoxy-4-methyl-1,4-benzothiazepine Basic information |
| Product Name: | 2,3,4,5-Tetrahydro-7-methoxy-4-methyl-1,4-benzothiazepine | | Synonyms: | 2,3,4,5-Tetrahydro-7-methoxy-4-methyl-1,4-benzothiazepine;2,3,4,5-Tetrahydro-7-methoxy-4-methyl-;S 107 hydrochloride;S107;S-107; S 10;CS-2452;7-methoxy-4-methyl-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine;1,4-Benzothiazepine, 2,3,4,5-tetrahydro-7-methoxy-4-methyl- | | CAS: | 927871-76-9 | | MF: | C11H15NOS | | MW: | 209.31 | | EINECS: | | | Product Categories: | API | | Mol File: | 927871-76-9.mol |  |
| | 2,3,4,5-Tetrahydro-7-methoxy-4-methyl-1,4-benzothiazepine Chemical Properties |
| Boiling point | 318.8±42.0 °C(Predicted) | | density | 1?+-.0.06 g/cm3(Predicted) | | storage temp. | 2-8°C | | pka | 7.74±0.20(Predicted) | | form | Solid | | color | White to off-white | | Water Solubility | Water : ≥ 132 mg/mL (537.09 mM) | | BRN | 18342799 |
| Hazard Codes | Xn | | Risk Statements | 22 | | WGK Germany | 3 |
| | 2,3,4,5-Tetrahydro-7-methoxy-4-methyl-1,4-benzothiazepine Usage And Synthesis |
| Uses | It is a benzothiazepine derivative that binds the RyR1 channel and enhances the binding affinity of Calstabin-1. By preventing the depletion of Calstabin-1 from the RyR1 complex, S 107 slows muscle fatique and reduces muscle damage in exercised mice. In a murine model of Duchenne muscular dystrophy, S 107 reduces biochemical and histological evidence of the muscle damage associated with muscular dystrophy, improves muscle function, and increases exercise performance. |
| | 2,3,4,5-Tetrahydro-7-methoxy-4-methyl-1,4-benzothiazepine Preparation Products And Raw materials |
|